← All trials
NCT01442649
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2010
- Primary completion
- Oct 1, 2015
- Completion date
- Dec 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 132
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- UNICANCERLead sponsor
- Centre Hospitalier du Mittan-MONTBELIARDOverall official - principal investigator
- Groupe hospitalier St Joseph-PARISOverall official - principal investigator
- Centre Hospitalier CholetOverall official - principal investigator
- University of PoitiersOverall official - principal investigator
- University of Franche-ComtéOverall official - principal investigator
- University of LyonOverall official - principal investigator
- University of ToulouseOverall official - principal investigator
- Centre hospitalier du MansOverall official - principal investigator
- University of LorraineOverall official - principal investigator
- Centre Paul StraussOverall official - principal investigator
- Aix-University of MarseilleOverall official - principal investigator
- University of BordeauxOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
- University of LilleOverall official - principal investigator
- Institut de Cancerologie de l'Ouest Paul PapinOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.